Status: Recruiting
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.
Participants needed: 34,532
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: BioDelivery Sciences InternationalUpdated: Feb 12, 2025Locations: 1
Eligibility criteria
At least one dispensing of naldemedine or lubiprostone or naloxegol without prio... [+3]
Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on... [+2]